NuProbe will integrate QASeq and BDA technologies with Bionano’s Saphyr system for research and product development in the fields of reproductive health and oncology liquid biopsies.
Read More
<
Introducing the VarTrace® MSI qPCR Assay. Learn More
Introducing our Product Proof of Concept Program. Learn More
Join us at the PMWC 2021 Pittsburgh, September 23-24, 2021
>
Technology
Blocker Displacement
Amplification
Rare allele enrichment technology by PCR that enables the selective amplification and detection of low-abundant sequence variants down to 0.01% variant allele frequency (VAF).
Quantitative Amplicon
Sequencing
NGS-based method that utilizes unique molecular identifiers (UMIs) and highly-multiplexed partiallynested PCR primer design to detect mutations and copy number variations with high sensitivity.
Products & Services
VarMap® Pan-Cancer NGS Panel
The only liquid biopsy panel to detect 0.1% VAF requiring only 1 million NGS reads
Overview
The VarMap Pan-Cancer NGS Panel enables highly-sensitive variant detection and quantitation across hundreds of loci in 61 genes. Utilizing BDA technology and next generation sequencing, the VarMap Pan-Cancer panel significantly improves the limit of detection (≥0.1% VAF) while reducing the number or reads required. The panel is compatible with a number of sample types including cell-free DNA, tumor sections, and PMBC DNA.
Key Features
- Detect SNVs and indels down to 0.1% VAF
- Requires only 1 million NGS reads per sample
- Compatible with tumor-derived or cell-free DNA
- Simple and user-friendly workflow and bioinformatics
CNV+ Breast Cancer NGS Panel
Accurately detect SNVs and indels in 14 genes and CNVs across 18 genes associated with breast cancer
Overview
The CNV+ Breast Cancer NGS Panel covers 84 frequently mutated breast cancer hotspots in 14 genes and CNVs of 18 genes including HER2. Using QASeq technology, the CNV+ Breast Cancer NGS Panel accurately quantifies SNVs and indels down to 0.2% VAF as well as detect CNVs in HER2 at 2.04/1.97 single heterozygous copy gain/loss from cfDNA or tumor tissue.
Key Features
- Detect SNVs and indels at 0.2% VAF
- Detect CNVs at 2.04/1.94 ploidy
- Compatible with tumor-derived or cell-free DNA
VarTrace® MSI Assay
Highly sensitive detection of detection of microsatellite instability in five MSI loci using qPCR.
Overview
NuProbe’s VarTrace MSI Assay enables detection of MSI high (MSI-H) status with a limit of detection to 1% in five mononucleotide markers (BAT-25, BAT-26, NR-21, NR-24 and MONO-27).
Key Features
- Matched normal not required
- Results in less than two hours
- Compatible with tumor tissue or cell-free DNA
- Limit of detection down to 1% VAF
VarTrace® qPCR/Sanger Assays
qPCR/Sanger assays to identify variants down to 0.1% VAF
Key Features
- Detect targeted variants down to 0.1% VAF
- Same day results
- Compatible with a variety of instruments
Augury™ Biopharma Services
Custom solutions for your company’s biomarker needs
Overview
The Augury Biopharma Services leverages our proprietary technologies to create optimal solutions for your process, across test modalities such as next-generation sequencing (NGS) and PCR. The flexibility of our platform facilitates design of custom solutions across numerous disease and application areas.
Key Features
- Solutions for every step from research use only to clinical trial
- Assay development and validation, kit manufacturing, and sample testing services
- Proprietary PCR and NGS technologies compatible with liquid biopsy and tissue samples
- Best-in-class sensitivity to detect a wide range of alterations
Accelerating Precision Oncology Worldwide
Clinical and Research Laboratories
At NuProbe, we are developing innovative assays to accelerate cancer research. Our products allow laboratories to detect and quantify low abundant variants across multiple platforms from both cell-free DNA and tissue specimens. Contact us today to learn more.
Pharma
Assay development and testing services to support all stages of biomarker detection programs. Our flexible platform utilizes proprietary technologies to deliver best-in-class sensitivity from solid tumor and liquid biopsy. Contact one of our experts today to find out what NuProbe can do for you.
Never miss an update
Stay in touch for the latest NuProbe developments
News & Press Releases
NuProbe published research on DNA microsatellites in Nucleic Acids Research and released VarTrace® MSI qPCR research use only assay.
Research published in Nature Biomedical Engineering demonstrates NuProbe’s technology can enable detecting SNVs in DNA with a VAF of ≤0.02% using a sequencing depth of only 250x.
The VarMap Pan-Cancer NGS Panel uses the quantitative blocker displacement amplification technology to enrich, detect, and quantitate over 6500 mutations and indels in 61 clinically relevant genes. The panel can be used on cfDNA samples to detect mutations down to 0.1% variant allele frequency (VAF) using only 1 million NGS reads. The panel can also be applied to FFPE tumor samples or other cellular samples for minimum residual disease (MRD) detection, detecting mutations down to 0.01% VAF.
The lead investors for this financing round are BioTrack Capital and Yonghua Capital. The proceeds will be used to expand the commercial team in both the US and China, develop new NGS products, and file for regulatory approval in China for NuProbe’s clinical products.
Upcoming Events
September 23-24, 2021
September 29-30, 2021
11th World Clinical Biomarkers & CDx Summit
Oct 18-22, 2021
Nov 16-20, 2021
